Evofosfamide (development code TH-302) is an investigational new drug that is being evaluated for the treatment of multiple tumor types, including pancreatic cancer, soft tissue sarcoma, and multiple myeloma, often in combination with other therapies. It is a hypoxia-activated prodrug designed to target and kill hypoxic cells within tumors. It functions by releasing the DNA crosslinking agent bromo-isophosphoramide mustard under low oxygen conditions, making it potentially effective against tumor regions where standard chemotherapy and radiation therapies are less effective due to hypoxia.
Commercialization has not been pursued due to the failure of several clinical trials.
Pharmacology
Evofosfamide is a 2-nitroimidazole prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM). Evofosfamide is activated by a process that involves a 1-electron (1 e−) reduction mediated by ubiquitous cellular reductases, such as the NADPH cytochrome P450, to generate a radical anion prodrug: A) In the presence of oxygen (normoxia) the radical anion prodrug reacts rapidly with oxygen to generate the original prodrug and superoxide. Therefore, evofosfamide is relatively inert under normal oxygen conditions, remaining intact as a prodrug. B) When exposed to severe hypoxic conditions (< 0.5% O2; hypoxic zones in many tumors), however, the radical anion undergoes irreversible fragmentation, releasing the active drug Br-IPM and an azole derivative. The released cytotoxin Br-IPM alkylates DNA, inducing intrastrand and interstrand crosslinks.
Evofosfamide is largely inactive under normal oxygen levels. In areas of hypoxia, evofosfamide becomes activated and converts to an alkylating cytotoxic agent resulting in DNA cross-linking. This renders cells unable to replicable their DNA and divide, leading to apoptosis. This investigational therapeutic approach of targeting the cytotoxin to hypoxic zones in tumors may cause less broad systemic toxicity that is seen with untargeted cytotoxic chemotherapies.
The activation of evofosfamide to the active drug Br-IPM and the mechanism of action (MOA) via cross-linking of DNA is shown schematically below:
Drug development history
Phosphorodiamidate-based, DNA-crosslinking, bis-alkylator mustards have long been used successfully in cancer chemotherapy and include e.g. the prodrugs ifosfamide and cyclophosphamide. To demonstrate that known drugs of proven efficacy could serve as the basis of efficacious hypoxia-activated prodrugs, the 2-nitroimidizole HAP of the active phosphoramidate bis-alkylator derived from ifosfamide was synthesized. The resulting compound, TH-281, had a high HCR (hypoxia cytotoxicity ratio), a quantitative assessment of its hypoxia selectivity. Subsequent structure-activity relationship (SAR) studies showed that replacement of the chlorines in the alkylator portion of the prodrug with bromines improved potency about 10-fold. The resulting, final compound is evofosfamide, which was developed by Threshold Pharmaceuticals. Threshold Pharmaceuticals Inc. applied for a patent on evofosfamide in 2006 which was granted in 2011.
In 2012, Threshold signed a global license and co-development agreement for evofosfamide with Merck KGaA. Threshold was responsible for the development of evofosfamide in the soft tissue sarcoma indication in the United States. In all other cancer indications, Threshold and Merck KGaA developed evofosfamide together. After evofosfamide failed to improve longevity in patients in phase three clinical trials, Merck abandoned attempts to commercialize evofosfamide in 2015.
Synthesis
Evofosfamide can be synthesized in seven steps.Synthetic route Reference: International patent application WO2007002931A2
Clinical trials
Overview and results
Evofosfamide was evaluated in clinical studies as a monotherapy and in combination with chemotherapy agents and other targeted cancer drugs. The indications were a broad spectrum of solid tumor types and blood cancers.
Evofosfamide clinical trials (as of 16 March 2025):
Clinical Trials of Evofosfamide NCT ID Title Phase Study Status Dose-Escalation Study of TH-302 PHASE1 COMPLETED Study of the Safety and Efficacy of TH-302 PHASE2 COMPLETED Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias PHASE1 COMPLETED Dose-Escalation Study of TH-302 in Combination With Sunitinib PHASE1 UNKNOWN Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma PHASE2 COMPLETED A Trial of TH-302 in Combination With Doxorubicin PHASE2 COMPLETED Dose Escalation Study of Pazopanib Plus TH-302 PHASE1 COMPLETED Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Advanced Kidney or Liver Cancer PHASE1 COMPLETED Open-label Study of TH-302 and Dexamethasone PHASE1 UNKNOWN TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) PHASE1 UNKNOWN Clinical Trial Testing TH-302 in Combination With Gemcitabine PHASE3 COMPLETED A Japanese Phase 1 Trial of TH-302 PHASE1 COMPLETED A Phase 2 Biomarker-Enriched Study of TH-302 in Advanced Melanoma PHASE2 TERMINATED A Cardiac Safety Study of TH-302 PHASE1 UNKNOWN Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel PHASE1 TERMINATED A Phase 1 TH-302 Mass Balance Trial PHASE1 COMPLETED Study of TH-302 or Placebo in Combination With Pemetrexed PHASE2 TERMINATED A Japanese Trial of TH-302 in Soft Tissue Sarcoma PHASE2 TERMINATED TH-302 in Combination With Bevacizumab for Glioblastoma PHASE2 COMPLETED A Study to Assess the Safety and Efficacy of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours PHASE1 COMPLETED Study of TH-302 Monotherapy as Second-line Treatment in Biliary Tract Cancer PHASE2 COMPLETED A Study of Hypoxia Imaging in Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 NA WITHDRAWN Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer PHASE1 WITHDRAWN SARC021C: A Continuation Study of TH-CR-406/SARC021 NA NO_LONGER_AVAILABLE Immunotherapy Study of Evofosfamide in Combination With Ipilimumab PHASE1 UNKNOWN A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab PHASE1 RECRUITING Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer PHASE2 NOT_YET_RECR
Soft tissue sarcoma
Evofosfamide was tested in combination with doxorubicin in patients with advanced soft tissue sarcoma. The study TH-CR-403 was a single arm trial investigating evofosfamide in combination with doxorubicin. Evofosfamide was further tested in the Phase 3 clinical trial TH-CR-406/SARC021 with results published in 2017 indicating no improvement in patient mortality rates.
Metastatic pancreatic cancer
Evofosfamide was studied in combination with gemcitabine in patients with metastatic pancreatic cancer. The study TH-CR-404 compared gemcitabine with gemcitabine plus evofosfamide. The study showed comparable efficacy profiles for evofosfamide and nab-paclitaxel when combined with gemcitabine; however, the hematologic toxicity was higher for patients given evofosfamide vs. nab-paclitaxel.
In the Phase 3 MAESTRO study, patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with evofosfamide in combination with gemcitabine did not demonstrate a statistically significant improvement in overall survival.
Nasopharyngeal carcinoma Oxygen deficient conditions are linked to tumor progression throughout the body and poses an issue in cancer treatments such as chemotherapy and radiation. Hypoxia-activated prodrugs (HAPs) function in hypoxic conditions and inhibit the growth of tumor cells. Evofosfamide is a HAP that targets tumor progression in nasopharyngeal carcinoma (NPC) tissues by inhibiting the overexpression of hypoxia-inducible factor-1α (HIF-1α).
In this study, the efficacy of Evofosfamide along with cisplastin (DDP) in blocking cell progression was measured. "The combination of evofosfamide with DDP had a synergistic effect on cytotoxicity in the NPC cell lines by combination index values assessment. Cell cycle G2 phase was arrested after treated with 0.05 μmol/L evofosfamide under hypoxia. Histone H2AX phosphorylation (γH2AX) (a marker of DNA damage) expression increased while HIF-1α expression suppressed after evofosfamide treatment under hypoxic conditions". These findings allow for evidence for Evofosfamide to be pushed towards clinical trials to further investigate the potential to be developed as an FDA approved anticancer drug.
See also Hypoxia-activated prodrugs Hypoxia PR-104
References